

HOTLINE: Effective January 27, 2022

New Test	3004572 Multiple Endocrine Neoplasia Type 2 (MEN2), <i>RET</i> Sequencing MEN2 NGS					
Available Now	7					
	Patient History for Multiple Endocrine Neoplasia 2, RET Gene Testing				ation	
Methodology:	Massively Parallel Sequencing					
Performed:	Varies	Varies				
Reported:	3 weeks					
Specimen Required: Collect: Lavender or pink (EDTA) or yellow (ACD solution A or B).   Specimen Preparation: Transport 3 mL whole blood. (Min: 2 mL)   Storage/Transport Temperature: Refrigerated.   Unacceptable Conditions: Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.   Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable						
Reference Interval: By report						
Interpretive Da Refer to report.	ta:					
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.						

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Gene Tested: *RET* (NM\_020975)

**CPT Code(s):** 81406

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.